Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TheraclionTCLIF 27 PS Ratio is 19.70 as of Aug. 01, 2026, which is 32% above its 10-year median of 14.89. GuruFocus rates TCLIF with a GF Score™ of 27/100 and a GF Value™ of $0.23. The stock has 7 warning signs investors should review. Among 803 Medical Devices & Instruments companies, Theraclion ranks worse than 92.4% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Theraclion's share price is $0.532.
Theraclion's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.03. Hence, Theraclion's PS Ratio for today is 19.70.
The historical rank and industry rank for Theraclion's PS Ratio or its related term are showing as below:
TCLIF'
s PS Ratio Range Over the Past 10 Years
Min: 1.97 Med: 14.89 Max: 50.14
Current: 24.71
During the past 13 years, Theraclion's highest PS Ratio was 50.14. The lowest was 1.97. And the median was 14.89.
TCLIF's PS Ratio is ranked worse than 92.4% of 803
companies
in the Medical Devices & Instruments industry
Industry Median: 2.91
vs TCLIF: 24.71
Theraclion revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Theraclion was 5.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -20.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -20.60% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -28.20% per year.
During the past 13 years, Theraclion's highest 3-Year average Revenue per Share Growth Rate was 283.90% per year. The lowest was -58.30% per year. And the median was -20.60% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Theraclion PS Ratio Related Terms
Theraclion PS Ratio Historical Data
* Premium members only.
The historical data trend for Theraclion's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Theraclion's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theraclion PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Theraclion's PS Ratio distribution charts can be found below:
* The bar in red indicates where Theraclion's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Theraclion's Share Price of today is $0.532.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Theraclion's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Theraclion (TCLIF) has a PS Ratio of 19.70 as of Aug. 01, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Theraclion and its competitors. This is 32% above median its historical median of 14.89. Over the past decade, Theraclion's PS Ratio has ranged from 1.97 to 50.14. According to the industry distribution chart, Theraclion ranks #742 out of 803 companies in the Medical Devices & Instruments industry, placing it in the top 92.4%.
Is Theraclion's PS Ratio too high?
Theraclion's current PS Ratio of 19.70 is 32% above median its 10-year median of 14.89. Over the past 10 years, this metric has ranged from a low of 1.97 to a high of 50.14. The Medical Devices & Instruments industry median PS Ratio is 2.91. Theraclion's value of 19.70 is 577% above this industry median. Based on the distribution chart, Theraclion ranks #742 out of 803 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Theraclion has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Theraclion's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Theraclion ranks #742 out of 803 companies for PS Ratio. This places Theraclion in the lower half of its industry. The industry median PS Ratio is 2.91. Theraclion's value of 19.70 is 577% above this benchmark. Historically, Theraclion's own PS Ratio has ranged from 1.97 to 50.14 over the past decade. While the company's 10-year median is 14.89 vs. the industry median of 2.91, Theraclion has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.91, based on 803 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Theraclion's current PS Ratio of 19.70 is 577% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Theraclion and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theraclion's current PS Ratio is 19.70, which is 32% above median its own 10-year median of 14.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theraclion stock overvalued right now?
Theraclion (TCLIF) has a current PS Ratio of 19.70. The stock's GF Value™ is $0.23, compared to a current price of $0.53 — trading 131.3% above its estimated fair value. The current PS Ratio is 19.70, which is 32% above median its 10-year median of 14.89 and 577% above the Medical Devices & Instruments industry median of 2.91. Theraclion's overall GF Score™ is 27/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Theraclion (TCLIF), the current PS Ratio is 19.70 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theraclion (TCLIF) Overvalued in 2026?
Based on GuruFocus' analysis, Theraclion stock appears to be overvalued.
The current stock price of $0.53 is trading 131.3% above its estimated GF Value™ of $0.23.
Key valuation signals for TCLIF:
PS Ratio: 19.70 (32% above median its 10-year median of 14.89)
GF Value™: $0.23 vs. price of $0.53 (131.3% above fair value)
Industry Position: 577% above the Medical Devices & Instruments median (#742 of 803)
No single metric tells the full story. See the TCLIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theraclion specializes in developing, manufacturing, and marketing echotherapy equipment, associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules. Its products include Sonovein, Echopulse, and Epack.
27GF Score
Get the complete analysis for TCLIF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TCLIF has been successfully added to your 
